Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine-based first-line therapy for indolent B‑cell non-Hodgkin lymphoma (real-world registry)
ChiCTR2000039605Phase 4Recruiting
- Sponsor
- Harbin First Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bendamustine in mature B-cell lymphoma, follicular lymphoma (FL), Waldenström macroglobulinemia (WM) and 2 more, sponsored by Harbin First Hospital. Primary endpoint: overall response rate. Started Oct 2020; status: recruiting.
02
Drugs
bendamustine
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)Waldenström macroglobulinemia (WM)marginal zone B-cell lymphoma (MZL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2000039605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039605.